About ZemairaWhat is Alpha-1?Patient SupportPatient SupportFor Healthcare ProfessionalsPrescribing InformationImportant Safety InformationAlready Treating Your Alpha-1?Newly diagnosed with alpha-1?Diagnosed with Chronic Lung Disease?Receive Zemaira at no charge for up to 2 weeks.

My Steps for Healthy Living - Registration Page

Sign up now to register for the My Steps for Healthy Living Program
How My Steps For Healthy Living Works:
  1. After you enroll, you'll receive a welcome packet with an outline of the program, your pedometer, a log sheet to record your steps, and a postage-paid "report card."
  2. At the end of each month record your steps on the report card and mail it back. Your goal is to increase your number of steps by 10% each month. If you have not been able to increase your steps by 10% this past month, don't worry—but don't give up! Remember: You don't have to walk fast or for long periods of time to get benefits!
  3. After you mail back your report card, you will receive a motivational reward as well as a new report card to record your steps for the next month. It is our way of congratulating you for a job well done. We want to help you keep your momentum going. So keep rising to the challenge by walking a little more each day.

  • All fields marked with an asterisk(*) are required.
  •  
  •  
  •  
  •  


    •    

  • Prior to submitting your information, please review our Privacy Policy.

    I would like to unsubscribe from this e-mail program.

    CSL Behring will keep any information you provide in strict confidence, and will not share or otherwise disclose such information without your express permission.

Important Safety Information

Alpha1-Proteinase Inhibitor (Human), Zemaira is indicated for chronic augmentation and maintenance therapy for adults with alpha1-proteinase inhibitor (A1-PI) deficiency and emphysema. Clinical data demonstrating the long-term effects of chronic augmentation therapy with Zemaira are not available.

Zemaira may not be appropriate for the following adult individuals as they may experience severe reactions, including anaphylaxis: individuals with a known hypersensitivity and/or history of anaphylaxis or severe systemic reaction to A1-PI products or their components, and individuals with selective IgA deficiencies who have known antibodies against IgA.

In clinical studies, the following treatment-related adverse reactions were reported in 1% of subjects: asthenia (fatigue), injection-site pain, dizziness, headache, paresthesia (tingling), and pruritus (itching).

Zemaira is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

Please see full prescribing information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.